Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17687887 | 1.00 | USP30 (0.44) | USP30PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17687891 | 1.00 | USP30 (0.44) | USP30PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17687870 | 0.93 | USP30 (0.39) | USP30PDE4BHPGDSCHEK2 | |
| SCHEMBL17687943 | 0.84 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL17687945 | 0.84 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL17687878 | 0.84 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGPDE4B | |
| SCHEMBL17687865 | 0.84 | USP30 (0.45) | USP30PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17687866 | 0.84 | USP30 (0.45) | USP30PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17688021 | 0.83 | SOS1 (0.38) | — | |
| SCHEMBL19471375 | 0.83 | SOS1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207042-B1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-9850256-B2 | Antibacterial basic biaromatic derivatives with aminoalkoxy substitution | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305927-A1 | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION | RPSA, RPL4, RPS4Y1 | USP30 1237/4885PIK3CD 1792/4885PIK3CA 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.